NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Innoviva, Inc. (INVA) Stock Analysis

Innoviva, Inc. (INVA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

INVA

$21.33

−$0.02 (−0.09%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INVA with… →

INVA Key Statistics

As of Sep 4, 2026
Trading
Open
$21.20
Previous Close
$21.35
Day's Range
21.09–21.36
52-Week Range
16.52–25.15
Volume
563.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.33
Valuation
Market Cap
$1.54B
P/E Ratio
4.95
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.65
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.26
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.50
EPS (ttm)Profit attributable to each share over the last twelve months.
4.31
Financials (FY)
Revenue (FY)
$411.33M+14.67%
Net Income (FY)
$271.17M+1059.22%
Profit marginThe share of revenue left as profit after all costs and taxes.
81.19%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
72.25M
1-Year Return
+1.96%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
759.12K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

INVA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+6.70%
2025+15.22%
2024+8.17%
2023+21.06%
2022−23.19%
2021+39.23%
2020−12.50%
2019−18.85%
2018+22.97%
2017+32.62%
2016 (partial year)−14.47%

As of September 4, 2026.

INVA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$411.33M$271.17M65.9%
2024$358.71M$23.39M6.5%
2023$310.46M$179.72M57.9%
2022$331.34M$213.92M64.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$411.33M$333.94M$163.75M$271.17M65.9%
2024$358.71M$322.11M$166.87M$23.39M6.5%
2023$310.46M$267.82M$113.89M$179.72M57.9%
2022$331.34M$317.55M$207.00M$213.92M64.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

INVA Valuation vs Biotechnology Median

Median of 656 stocks
MetricINVABiotechnology medianvs median
P/E4.9512.5761% below
P/S ratio3.5015.260.2x the median
Profit margin81.19%0.00%81.2 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Innoviva, Inc. (INVA) is capitalised at $1.54B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 159 employees.

The 52-week range on file runs from $16.52 to $25.15. The most recent close on file for INVA is $21.33, dated September 4, 2026. That is −$0.02 (−0.09%) against the previous close. The latest close sits 29.12% above that 52-week low.

Financial Health

In fiscal 2025, Innoviva, Inc. reported revenue of $411.33M. That is +14.67% against the prior fiscal year, when revenue was $358.71M. The same year closed with net income of $271.17M. That is +1,059.22% against the prior fiscal year. Profit margin runs at 81.19%. That is 81.2 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 4.31.

Across the 4 fiscal years on file, revenue moves from $331.34M in 2022 to $411.33M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 4.95 times earnings. That is 60.62% below the Biotechnology median of 12.57. The forward P/E on file is 9.65. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.26. The price-to-sales ratio is 3.5. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.33. Annualized volatility over the trailing 10 years is 33.48%. The trailing one-year price return is +1.96%. Measured over 10 years, that is +6.76% a year compounded.

Growth & Income

No dividend is on file for INVA.

So far in 2026 the price is +6.70%. The strongest complete calendar year on file is 2021 at +39.23%; the weakest is 2022 at −23.19%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Innoviva, Inc. (INVA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Innoviva, Inc. INVA $1.54B 5.0
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Innoviva, Inc. trades at a P/E of 5.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Innoviva, Inc.

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Visit website →